Treatment for Pan-Resistant Klebsiella pneumoniae Infection

First-Line Treatment Options

The International Society for Antimicrobial Chemotherapy recommends ceftazidime/avibactam or meropenem/vaborbactam as first-line treatment options for KPC-producing Carbapenem-Resistant Klebsiella pneumoniae when available, with superior clinical outcomes compared to traditional antibiotic regimens 1
Ceftazidime/avibactam has shown significantly higher clinical success rates and lower 28-day mortality (18.3% vs 40.8%) compared to other regimens in patients with KPC-producing K. pneumoniae bloodstream infections 1

The European Society of Clinical Microbiology and Infectious Diseases suggests imipenem/relebactam and cefiderocol as alternative options when first-line agents are unavailable 1
For infections susceptible to sulbactam, ampicillin-sulbactam can be considered, particularly for respiratory infections, according to the Clinical Microbiology and Infection guidelines 2

The Clinical Microbiology and Infection guidelines suggest treatment with more than one drug active in vitro for severe infections caused by CRE susceptible only to polymyxins, aminoglycosides, tigecycline, or fosfomycin 2
Carbapenem-based combination therapy should be avoided unless the meropenem MIC is ≤8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination therapy, as recommended by the Clinical Microbiology and Infection guidelines 2

For non-severe infections, monotherapy with an in vitro active agent may be considered on an individual basis according to the source of infection, as suggested by the Clinical Microbiology and Infection guidelines 2
The choice should be guided by the least resistant antibiotic based on MICs relative to the breakpoints, according to the Clinical Microbiology and Infection guidelines 3

Optimal source control should always be a priority to improve outcomes and potentially shorten antibiotic treatment durations, as recommended by the Clinical Microbiology and Infection guidelines 3
Optimal antibiotic dosing schemes should be used, with attention to adverse effects, and therapeutic drug monitoring should be utilized whenever available, as suggested by the Clinical Microbiology and Infection guidelines 3

The World Journal of Emergency Surgery recommends that extended use of cephalosporins should be discouraged in settings with high incidence of ESBL-producing Enterobacteriaceae, and carbapenems should be preserved and used judiciously due to increasing carbapenem resistance among Enterobacteriaceae 4

The Centers for Disease Control and Prevention recommends that all patients with carbapenem-resistant Enterobacteriaceae should be managed using contact precautions, and active surveillance cultures should be performed for patients with epidemiologic links to persons from whom CRE have been recovered 5